Introduction
============

The highest rates of cancer-related mortality are associated with breast, prostate and lung cancer, as reported by the World Health Organization ([@b1-ol-0-0-7508]), the World Cancer Report ([@b2-ol-0-0-7508]) and Cancer facts and figures ([@b3-ol-0-0-7508]) A plethora of cancer microarray and RNA sequencing (RNA-Seq) studies are publicly available in databases, including the Gene Expression Omnibus (GEO) ([@b4-ol-0-0-7508]), Array Express ([@b5-ol-0-0-7508]) and The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>). Recently, simultaneous analysis and comparison of the results from microarray and RNA-Seq data has been explored ([@b6-ol-0-0-7508]--[@b8-ol-0-0-7508]). These studies have indicated that RNA-Seq has more benefits compared with microarray platforms, including broader dynamic range and increased specificity and sensitivity, however using the samples belonging to the same biological conditions from both the platforms produces highly correlated gene expression profiles. However, microarrays remain a popular choice amongst researchers when conducting transcriptional profiling experiments, because RNA-Seq technology is novel, more expensive, and requires extensive and complex data storage and analysis. When analysis is conducted on both platforms, strongly concordant and highly correlated results are obtained ([@b6-ol-0-0-7508],[@b7-ol-0-0-7508]). The present study focused on microarray analysis, but additionally performed analysis on RNA-Seq data, so as to validate the significance of the results obtained. Several studies in recent years have reported meta-analysis of such data, where the analyses are performed on integrated samples from multiple microarray datasets ([@b9-ol-0-0-7508]--[@b13-ol-0-0-7508]). The majority of the articles focusing on meta-analysis use the following strategies: assembling published differential expressed gene (DEG) lists from experimental studies and then articulating the consistently reported DEGs ([@b14-ol-0-0-7508]--[@b16-ol-0-0-7508]); or integrating multiple datasets from different microarray platforms and then executing statistical tests to discover consistently expressed DEGs ([@b9-ol-0-0-7508]--[@b13-ol-0-0-7508]). However, inconsistencies in the results are observed due to technical limitations, such as variance in expression measurements and differences in laboratory protocols for different microarray platforms. One major inconsistency reported in meta-signature studies is the overrepresentation of genes common to various platforms, and the underrepresentation of genes which are not common to different platforms ([@b11-ol-0-0-7508]). In addition, meta-analysis that uses previously published DEG lists when raw data are unavailable, has the limitation that it is difficult to assign a confidence for combined P-values and fold change measurements for each gene ([@b14-ol-0-0-7508]).

With a purview to improve the understanding of cancer pathogenesis, and based on the methods from the published literature, the present study applied differential gene expression analysis individually to six microarray datasets and one RNA-Seq dataset, representing three different cancer types, breast, lung, and prostate. The aim of the present study was to discover a common set of genes, which may demonstrate a significant expression pattern across these three cancer types. A common subset of DEGs was then explored by comparing the gene lists obtained from microarray and RNA-Seq analysis results. The resulting gene set was further analyzed by Gene Ontology (GO) functional annotations using GENECODIS ([@b17-ol-0-0-7508]), DAVID ([@b18-ol-0-0-7508]), Cancer Genetics Web ([@b19-ol-0-0-7508]), OMIM ([@b20-ol-0-0-7508]) and number of literature citations using TARGETgene ([@b21-ol-0-0-7508]). Furtemore, a meta-analysis of the combined samples was performed to identify the heterogeneity in expression of the obtained DEGs in all the six microarray datasets analyzed. This helped in observing the change in expression of the DEGs under different cancer conditions. It is an important implication that some genes always exhibit a consistent expression change, irrespective of the cancer type, whereas some genes exhibit inconsistency in expression change. This may aid oncologists in understanding the behavior of genes in cancer in terms of their heterogeneous expression.

Materials and methods
=====================

### Outline of data and preprocessing

Six cancer microarray datasets and one RNA-Seq dataset were downloaded from the GEO database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)) ([@b22-ol-0-0-7508]--[@b28-ol-0-0-7508]). The information extracted from each identified study is illustrated in [Table I](#tI-ol-0-0-7508){ref-type="table"}. The microarray analysis was restricted to datasets derived from two platforms, Affymetrix HGU-133A (GPL96) and Affymetrix HGU-133APlus2 (GPL570), which characterize probe sets with unique genes for Homo-Sapiens. The RNA-Seq dataset, GSE62944, comprises data from 24 cancer types from The Cancer Genome Atlas, and it is already processed using Rsubread R package and featureCounts() function in order to summarize the gene level expression values as integer numbers. In the present study, integer-based read counts were extracted for only the three cancer types of interest (breast, prostate and lung) out of the data matrix for 24 cancer types. The total number of samples analyzed was 454 (311 tumor samples/143 normal samples) and 2,333 (2,120 tumor samples/213 normal samples) for the microarray and RNA-Seq datasets, respectively. To ensure unregulated, unbiased, and consistent screening of the expression values from the different microarray datasets, the raw CEL files of the experiments were used. The Robust Multichip Average (RMA) technique, which performs quantile normalization, was the expression normalization technique used in the present study ([@b29-ol-0-0-7508]). This technique was applied to all individual raw microarray datasets in order to minimize inconsistencies due to normalization. This method of normalization was selected due to its good differential change detection, stable variance on log scale and reduced production of false positives. A comparison between different normalization methods has reported that RMA outperformed other methods in terms of specificity and sensitivity when dealing with fold change criteria in the detection of differential expression ([@b30-ol-0-0-7508]). The box plots of the RMA normalized intensity were plotted (data not shown), demonstrating that measurements of data were closely aligned towards a central mean, and were thus comparable.

### Identification of potentially significant target genes

The Bioconductor Linear Model for Microarray Analysis (LIMMA) package was used ([@b31-ol-0-0-7508]) to calculate the differential expression of each gene in the microarray and RNA-Seq datasets included in the present study. LIMMA remains highly recommended for such analyses ([@b32-ol-0-0-7508]). In a previous study comparing eight microarray analysis methods \[Welch\'s t-test, analysis of variance (ANOVA), Wilcoxon\'s test, significance analysis of microarrays (SAM), Randomized Variance Model (RVM), LIMMA, variance mixture (VarMixt) and structural model for variances (SMVar)\], LIMMA performed the best in terms of statistical power, false-positive rate, execution time and ease of use ([@b33-ol-0-0-7508]). In LIMMA, fitting of a linear model to the expression data for each probe is performed and the coefficients obtained describe the design matrix. Instead of simple t-statistics, it provides results for moderated t-statistic, moderated F-statistic, and B-statistic (which demonstrates the log-odds of differential expression), by applying the Empirical Bayes method and shrinking the standard errors towards a common value. Hence, LIMMA produces stable and reproducible results even with a small number of arrays. It also has the advantages of fast computation, simultaneous error rate control across multiple contrasts and genes, and effective prioritizing of results by applying a particular cutoff for fold change. For analysis of RNA-seq data, LIMMA with voom was used ([@b34-ol-0-0-7508]). The fitting of the mean-variance association into the differential expression analysis as a modification of limma\'s empirical Bayes procedure, and then converting it into a precision weight for each individual normalized observation is termed as limma-trend and voom. The performance of this method is best even when the sequencing depths are different for each RNA-sample.

### Functional annotation of DEGs

In an effort to infer the biological functions and signals involving the DEGs, GO enrichment analysis was performed. The online tool GENECODIS (<http://genecodis.cnb.csic.es>) was used for this purpose ([@b17-ol-0-0-7508]), which also provides pathway enrichment analysis based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The DAVID functional annotation tool was used for expounding the results of annotation ([@b18-ol-0-0-7508]).

### Literature citations for the DEGs

To confirm that the list of DEGs obtained in the present study is associated with cancer, the National Center for Biotechnology Information (NCBI; [www.ncbi.nlm.nih.gov](www.ncbi.nlm.nih.gov)) literature was searched to identify published reports relating these genes to cancer. The TARGETgene tool was used for this purpose ([@b21-ol-0-0-7508]). This tool identifies probable therapeutic targets in cancer by constructing a whole genome network using integration of heterogeneous data at the genomic and proteomic level. Upon the construction of the gene network, TARGETgene evaluates network-based parameters to detect potential therapeutic targets and displays the number of literature citations in all and individual cancer types for each gene, as reported in the NCBI database.

### Meta-analysis of expression heterogeneity of DEGs

Meta-analysis can refer to either the analysis of collectively published lists of DEGs, or the integration of diverse microarray datasets to perform a novel combined differential expression analysis. The meta-analysis performed in the present study investigated the diversity in expression of DEGs in six microarray datasets, collectively, with the aim to discover whether they display inconsistent expression changes in multiple studies, or whether they display consistent changes in all the analyzed studies. This is termed as heterogeneous or non-heterogonous behavior, respectively. This statistical heterogeneity implies genuine significant difference in between study variations, rather than within study variance which may be because of chance alone. Q and *I2* statistic tests remain the most widely used measures of heterogeneity for which computation modules are available in standard statistical software for meta-analysis, such as Stata and R ([@b35-ol-0-0-7508]). *I2* statistic is preferred among all measures of heterogeneity as it is a sample size and scale-invariant measure and has finite upper bounds and precise confidence intervals ([@b36-ol-0-0-7508]). For each gene obtained in the DEG list, analysis of heterogeneity was performed across cancer types using the meta package in R ([@b37-ol-0-0-7508]). A confidence interval of 95% was selected with the degree of freedom 5. The *metacont* function estimates the heterogeneity statistic score *I2*, along with the values, *Q, df*, and P-value. The seven suggested steps by Ramasamy *et al* ([@b38-ol-0-0-7508]), in conducting the meta-analysis of microarray datasets, were followed.

Results
=======

### Extracting significant gene markers relative to breast, lung and prostate cancer

The LIMMA R package was used to elucidate potential gene targets by adjusting the P-values using Benjamini-Hochberg correction. Genes were termed significantly differentially expressed if the adjusted P-value was \<0.05 and the fold change was \>2. DEGs for each microarray dataset of lung, breast and prostate cancer, were obtained individually, with results illustrated in [Table II](#tII-ol-0-0-7508){ref-type="table"}. Since datasets belonged to two platforms, GPL570 and GPL96, the number of probes was not equal in all datasets. Probes in GPL96 are a subset of probes in GPL570. Therefore, while combining the DEGs within the same cancer type, a union (merging) of the two individual lists of DEGs was performed, to get a single list of DEGs. The main aim of the present study was to find a common subset of DEGs across the three cancer types. Hence, an intersection of the DEG lists was performed to find members of the joint subset of genes across the three cancer types. Up to this stage of the analysis, mapping of probe IDs with the corresponding gene symbols was not performed. Therefore, the number of DEGs represented the unique probe IDs. In total, 75 differentially expressed probe IDs were discovered in common between the three cancer types. Following the removal of probes with no available annotation and the removal of repeated gene symbols, a list of 62 unique gene symbols was obtained as a result of the microarray data analysis.

A similar analysis was performed on the RNA-Seq data for the three individual cancer types. An integer-based raw gene count data matrix of breast, lung and prostate cancer samples was used with LIMMA and voom to explore the DEGs ([@b34-ol-0-0-7508]). The voom method estimates the mean variance relationship of the log counts, generates a precision weight for each observation and enters these into the LIMMA empirical Bayes analysis pipeline. Using this method, 1,290 genes were obtained in common across the three cancer types.

To confirm the consistency of the results obtained, genes appearing in both the microarray and RNA-Seq analysis results were identified. Following removal of all the duplicate gene symbols, a list of 44 genes was generated. The overlap of DEGs across the three cancers obtained from microarray analysis, from RNA-Seq analysis and from the combined microarray and RNA-Seq analysis is illustrated in [Fig. 1A-C](#f1-ol-0-0-7508){ref-type="fig"} respectively. The complete list of the genes identified by the combined microarray and RNA-Seq analysis, along with links to their description from the cancer genetics web ([@b19-ol-0-0-7508]) and OMIM database ([@b20-ol-0-0-7508]), is depicted in [Table III](#tIII-ol-0-0-7508){ref-type="table"}.

### Determination of functional annotation

The GENECODIS web software tool was used for functional annotation, which displays biological processes, molecular functions and cellular components that may be significantly enriched in a given gene list ([@b17-ol-0-0-7508]). The software also lists the KEGG pathways that may be significantly enriched in the gene list. The significance threshold of P\<0.05 was selected. The results are illustrated in [Figs. 2](#f2-ol-0-0-7508){ref-type="fig"}--[4](#f4-ol-0-0-7508){ref-type="fig"}. The terms involving two or more genes were retained in the graphs. The significantly enriched biological processes were multicellular organismal development, cell adhesion, axon guidance, cell differentiation, blood coagulation, muscle contraction, cell death, negative regulation of apoptotic process and anti-apoptosis ([Fig. 2](#f2-ol-0-0-7508){ref-type="fig"}). The significantly enriched molecular functions included protein, actin, calmodulin and syntaxin binding ([Fig. 3](#f3-ol-0-0-7508){ref-type="fig"}). The significantly enriched cellular components were the nucleus, cytoplasm, plasma membrane, cytosol, caveola, stress fiber, focal adhesion, extracellular matrix, extracellular region and cystoskeleton ([Fig. 4](#f4-ol-0-0-7508){ref-type="fig"}). Enriched KEGG pathways are listed in [Table IV](#tIV-ol-0-0-7508){ref-type="table"}. The detailed GO enrichment was also obtained by use of the DAVID functional annotation tool (data not shown) ([@b18-ol-0-0-7508]). Several functional predictions were provided by DAVID, including the presence of BIRC5 in cell survival pathway, TIMP3 in p53 signaling pathway, CAV1 in integrin signaling pathway, and CFD in alternative complement pathway given by BIOCARTA. COG (Clusters of Orthologous Group) Ontology predicted KIF4A involved in cell division and chromosome partitioning, and MYL9 involved in signal transduction mechanisms/cytoskeleton/cell division and chromosome. Significantly enriched biological processes were sensory perception, angiogenesis, cell cycle checkpoint, nuclear division, cytokinesis, apoptosis, cell death, and cell adhesion. Cellular components included extracellular region, cytosol, cell surface, cytoskeleton, nucleolus, cell fraction. Enriched KEGG pathways included pathways in cancer, transcriptional misregulation in cancer, focal adhesion, vascular smooth muscle contraction, MAPK signaling pathway, and the neurotrophin signaling pathway. In summary, the results from the function annotation analysis demonstrate a significant association of the discovered DEGs with cancer pathogenesis.

### Listing the literature citations

To explore the cancer-specific citations for these genes, and in particular the distribution of number of relevant citations in individual and/or all cancer types addressed in the present study, the TARGETgene tool was used ([@b21-ol-0-0-7508]). The results demonstrated a high ranking in literature from NCBI for the candidate key genes. These rankings are reported in [Table V](#tV-ol-0-0-7508){ref-type="table"}. Notably, the maximum number of citations in all cancers for these genes ranged from 1--326, with no gene having zero number of citations, suggesting that the key genes are relevant to cancer. When number of citations in individual cancers was considered, several genes had no relevant citations. For example, NTRK2 has zero NCBI citation in prostate cancer, whereas several studies report a role for this gene in prostate cancer ([@b39-ol-0-0-7508],[@b40-ol-0-0-7508]). Similarly, ID4 has been reported to have a role in lung cancer ([@b41-ol-0-0-7508]). A summary of the roles of these key genes in cancer is provided by cancer-genetics web database ([@b19-ol-0-0-7508]) and OMIM database ([@b20-ol-0-0-7508]) and listed in [Table III](#tIII-ol-0-0-7508){ref-type="table"}.

### Meta-analysis of the common set of DEGs

The *I^2^* statistic describes the % of variation across studies that is due to heterogeneity with a confidence interval constructed using the iterative Chi-squared distribution method. The *I*^2^ statistic ensures that better consistency measure between the trials would be obtained in meta-analysis ([@b35-ol-0-0-7508]). The calculation of *I*^2^ is obtained from *I*^2^=100×(Q−*df*)/Q, where Q denotes the Cochran\'s heterogeneity statistic and *df* denotes degree of freedom. The *I*^2^ value lies between 0 and 100%, with all negative values set to zero. The grading of heterogeneity based on *I*^2^ value is categorized at 25, 50 and 75% as low, moderate and high heterogeneity respectively. For each DEG, heterogeneity analysis was performed using the meta package in R ([@b37-ol-0-0-7508]), by extracting RMA normalized values from the six microarray datasets. However, these values could not be retrieved for all the 44 genes, as some probes were not present in data derived from the GPL96 platform. Therefore, heterogeneity analysis was performed only for those DEGs for which the probe ID measurements were available in all six datasets. The results of this analysis are listed in [Table VI](#tVI-ol-0-0-7508){ref-type="table"}. In this analysis, the P-value does not adequately describe the extent of heterogeneity in the results of the trials, whereas the *I*^2^ value does. Low *I*^2^ values indicate little variability between studies, with *I*^2^=0 meaning no heterogeneity. This non-heterogeneous behavior was observed in 6 genes out of the list of DEGs, namely CLU, EFEMP1, ID4, MCAM/MIR6756, PPAP2B, and DPT. The gene DPT was mapped by two different probe IDs, and therefore two different *I*^2^ values were obtained: one showed considerable heterogeneity, while the other showed no heterogeneity. The forest plots for some non-heterogeneous genes are illustrated in [Figs. 5](#f5-ol-0-0-7508){ref-type="fig"} and [6](#f6-ol-0-0-7508){ref-type="fig"} as an example. These plots demonstrated that the mean difference of individual studies is very close to, or almost similar to the mean of all the studies, which is depicted by the dashed vertical line. Similar forest plots were observed for all heterogeneous genes (data not shown).

Discussion
==========

The present analysis was motivated by previous research studies ([@b42-ol-0-0-7508]--[@b44-ol-0-0-7508]), where noteworthy genes were identified through bioinformatics analysis. The objective of the present study was to recognize common genetic indicators/biomarkers in lung, breast and prostate cancer, and to confirm their relevance in cancer by exploring NCBI citations using TARGETgene and by functional annotations using GENECODIS and DAVID. A robust gene set involved in the three cancer types was obtained, as microarray and RNA-Seq data were analyzed in combination in the present study. The RNA-Seq analysis proposed more genes compared with the microarray analysis to be involved in the process of oncogenesis. Further analysis would be required to classify these additional genes so that normal physiology could be attained by targeting cancer biomarkers. Further inspection of the obtained gene set for their inter-experiment behavior was performed to identify heterogeneity in expression. This is termed as meta-analysis as the normalized expression values from all available microarray data are combined. From this examination, it was evident that their comportment is subject to change in different types of cancers. A systematic review of between-study variance analysis demonstrated that some genes had no observed heterogeneity. These genes were CLU, EFEMP1, ID4, MCAM, PPAP2B and DPT, with *I*^2^ values 0, 1.1, 0, 0, 0 and 0% respectively. This indication of non-heterogeneous behavior across studies has inordinate importance from a biological perspective. Furthermore, some genes exhibited moderate heterogeneity, HSPB8, KCNAB1 and FXYD6 with *I*^2^ values 65.50, 64.50 and 27.10%, respectively. The DPT gene exhibited both types of behavior, which suggests that further experimental validation is required. The remaining genes had *I*^2^ values \>70%, suggesting considerable heterogeneity. Thus, the present analysis demonstrated the mining of noteworthy gene markers by analysis of both microarray and RNA-Seq data and by identifying a common set of genes relevant in the three cancer conditions. By ensuring that the Affymetrix gene chip platforms used for all the microarray data were similar, technical variation between platforms were avoided. In addition, by applying a similar method for normalizing expression and detecting differential genes to all datasets, the present investigation led to the discovery of a common subset of genes which displayed significantly variable expression between tumor and normal samples from microarray data analysis. Further analysis of RNA-Seq data from the same cancer types to obtain overlapping results, resulted in a more robust gene list. The e roles of these genes in carcinogenesis were further confirmed by the results from GENECODIS ([@b17-ol-0-0-7508]), DAVID ([@b18-ol-0-0-7508]), cancer genetics web ([@b19-ol-0-0-7508]), OMIM ([@b20-ol-0-0-7508]) and literature citations (by using TARGETgene) ([@b21-ol-0-0-7508]). Finally, statistical analysis of heterogeneity led to novel conclusions about their performance in the three different cancer types. Further studies would be of interest, including how the deregulation of apoptotic pathways may be one of the major roles the genes discovered in the present study may have.
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###### 

Characteristics of the individual datasets used in the present study.

  Type of dataset   Type of cancer                 Dataset identification number   Platform   Number of probes/genes   Number of samples (tumor/normal)
  ----------------- ------------------------------ ------------------------------- ---------- ------------------------ ----------------------------------
  Microarray        Breast                         GSE45827                        GPL570     54,675                   174 (163/11)
  gene expression                                  GSE48984                        GPL96      22,283                   22 (13/9)
                    Lung                           GSE19804                        GPL570     54,675                   120 (60/60)
                                                   GSE10072                        GPL96      22,283                   107 (57/50)
                    Prostate                       GSE55945                        GPL570     54,675                   19 (12/7)
                                                   GSE26910                        GPL570     54,675                   12 (6/6)
  RNA-Seq           Breast                         GSE62944                        GPL9052    23,368                   1,230 (1,118/112)
  gene expression   Lung squamous cell carcinoma                                                                       551 (501/50)
                    Prostate adenocarcinoma                                                                            552 (501/51)

###### 

Differential expression analysis results for each microarray dataset.

  Cancer              Breast             Lung               Prostate                                 
  ------------------- ------------------ ------------------ ------------------ ---------- ---------- ----------
  GEO dataset         GSE45827           GSE48984           GSE19804           GSE10072   GSE26910   GSE55945
  Platform            GPL570             GPL96              GPL570             GPL96      GPL570     GPL570
  Number of probes    54,675             22,283             54,675             22,283     5,4675     5,4675
  Number of samples   174                22                 120                107        12         19
  Number of           7,006              3,513              2,026              829        77         539
  differentially      Union of the two   Union of the two   Union of the two                         
  expressed genes     9,248              2,215              603                                      

###### 

Gene symbols of the common differentially expressed genes in breast, lung and prostate cancer.

  Gene symbol   Link to gene summary
  ------------- ------------------------------------------------------------------------------
  ACSS3         <https://www.omim.org/entry/614356?search=ACSS3&highlight=acss3>
  ANGPT1        <http://www.cancer-genetics.org/ANGPT1.htm>
  AOX1          <https://www.omim.org/entry/602841?search=AOX1&highlight=aox1>
  BIRC5         <http://www.cancer-genetics.org/BIRC5.htm>
  CAV1          <http://www.cancer-genetics.org/CAV1.htm>
  CAV2          <http://www.cancer-genetics.org/CAV2.htm>
  CCDC69        <http://www.genecards.org/cgi-bin/carddisp.pl?gene=CCDC69>
  CCDC85A       <http://www.genecards.org/cgi-bin/carddisp.pl?gene=CCDC85A&keywords=CCDC85A>
  CELF2         <https://www.omim.org/entry/602538?search=CELF2&highlight=celf2>
  CFD           <http://omim.org/entry/134350?search=CFD&highlight=cfd>
  CLU           <http://www.cancerindex.org/geneweb/CLU.htm>
  DPT           <https://www.omim.org/entry/125597?search=DPT&highlight=dpt>
  EFEMP1        <http://www.cancer-genetics.org/EFEMP1.htm>
  ERG           <http://www.cancer-genetics.org/ERG.htm>
  EZH2          <https://www.omim.org/entry/601573?search=EZH2&highlight=ezh2>
  FAM107A       <http://omim.org/entry/608295?search=FAM107A&highlight=fam107a>
  FERMT2        <https://www.omim.org/entry/607746?search=FERMT2&highlight=fermt2>
  FHL1          <http://omim.org/entry/300163?search=FHL1&highlight=fhl1>
  FXYD6         <http://omim.org/entry/606683?search=FXYD6&highlight=fxyd6>
  GLDN          <https://www.omim.org/entry/608603?search=GLDN&highlight=gldn>
  GPM6A         <http://omim.org/entry/601275?search=GPM6A&highlight=gpm6a>
  GPM6B         <http://omim.org/entry/300051?search=GPM6B&highlight=gpm6b>
  HSPB8         <http://omim.org/entry/608014?search=HSPB8&highlight=hspb8>
  ID4           <http://omim.org/entry/600581?search=ID4&highlight=id4>
  INMT          <https://www.omim.org/entry/604854?search=INMT&highlight=inmt>
  IQGAP3        <http://www.genecards.org/cgi-bin/carddisp.pl?gene=IQGAP3&keywords=IQGAP3>
  ITIH5         <https://www.omim.org/entry/609783?search=ITIH5&highlight=itih5>
  KCNAB1        <https://www.omim.org/entry/601141?search=KCNAB1&highlight=kcnab1>
  KIF4A         <http://omim.org/entry/300521?search=KIF4A&highlight=kif4a>
  MAMDC2        <https://www.omim.org/entry/612879?search=MAMDC2&highlight=mamdc2>
  MCAM          <http://www.cancer-genetics.org/MCAM.htm>
  MYH11         <http://www.cancer-genetics.org/MYH11.htm>
  MYL9          <http://www.cancer-genetics.org/PML.htm>
  MYLK          <https://www.omim.org/entry/600922?search=MYLK&highlight=mylk>
  NTRK2         <http://www.cancer-genetics.org/NTRK2.htm>
  NUSAP1        <http://omim.org/entry/612818?search=NUSAP1&highlight=nusap1>
  PCDH9         <http://omim.org/entry/603581?search=PCDH9&highlight=pcdh9>
  PGM5          <https://www.omim.org/entry/600981?search=PGM5&highlight=pgm5>
  PTRF          <http://omim.org/entry/603198?search=PTRF&highlight=ptrf>
  SDPR          <https://www.omim.org/entry/606728?search=SDPR&highlight=sdpr>
  STIL          <https://www.omim.org/entry/181590?search=STIL&highlight=stil>
  SYNPO2        <http://www.genecards.org/cgi-bin/carddisp.pl?gene=SYNPO2&keywords=SYNPO2>
  TCEAL2        <http://www.genecards.org/cgi-bin/carddisp.pl?gene=TCEAL2&keywords=TCEAL2>
  TIMP3         <https://www.omim.org/entry/188826?search=TIMP3&highlight=timp3>

###### 

Enriched KEGG pathways in differentially expressed genes as predicted by GENECODIS analysis.

  KEGG pathway                             Class                                     Number of genes   P-value (adjusted)   Gene symbols
  ---------------------------------------- ----------------------------------------- ----------------- -------------------- ------------------------
  Regulation of actin cytoskeleton         Cellular processes; cell motility         3                 0.016092             MYLK, IQGAP3, MYL9
  Vascular smooth muscle contraction       Organismal systems; circulatory system    3                 0.005475             MYLK, MYH11, MYL9
  Focal adhesion                           Cellular processes                        4                 0.003144             CAV2, MYLK, CAV1, MYL9
  Tight junction                           Cellular processes                        2                 0.039699             MYH11, MYL9
  Bacterial invasion of epithelial cells   Human diseases; infectious diseases       2                 0.016007             CAV2, CAV1
  Tryptophan metabolism                    Metabolism; amino acid metabolism         2                 0.01113              INMT, AOX1
  Viral myocarditis                        Human diseases; Cardiovascular diseases   2                 0.015622             CAV1, MYH11

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

TARGETgene results for differentially expressed gene ranking and their number of citations in all and individual cancer types.

  Rank   Gene symbol   Citation numbers for all cancers   Citation numbers for breast cancer   Citation numbers for prostate cancer   Citation numbers for lung cancer
  ------ ------------- ---------------------------------- ------------------------------------ -------------------------------------- ----------------------------------
    1    MYLK            4                                  3                                    1                                      0
    2    NTRK2         23                                   0                                    0                                      5
    3    CAV1          137                                46                                   24                                     22
    4    MCAM          22                                   3                                    6                                      1
    5    ANGPT1        35                                   3                                    0                                      3
    6    CAV2          24                                   6                                    4                                      2
    7    BIRC5         326                                47                                   18                                     46
    8    EFEMP1          4                                  1                                    0                                      2
    9    EZH2          68                                 37                                   33                                       6
  10     HSPB8         14                                   3                                    1                                      2
  11     ERG           35                                   0                                  67                                       2
  12     MYH11         16                                   1                                    1                                      0
  13     TIMP3         34                                   9                                    3                                      2
  14     MYL9            1                                  1                                    0                                      0
  15     SDPR            2                                  0                                    0                                      0
  16     PGM5            1                                  0                                    0                                      0
  17     CLU           48                                 11                                   18                                       8
  18     FHL1            5                                  1                                    1                                      0
  19     FXYD6           4                                  0                                    0                                      0
  20     KIF4A           8                                  0                                    1                                      0
  21     KCNAB1          2                                  0                                    0                                      0
  22     GPM6A           3                                  0                                    0                                      1
  23     CFD             1                                  0                                    0                                      0
  24     FAM107A         9                                  0                                    0                                      1
  25     PTRF            3                                  1                                    1                                      0
  26     DPT             3                                  0                                    0                                      0
  27     ID4           21                                   4                                    0                                      0
  28     FERMT2          4                                  1                                    0                                      2
  29     MAMDC2          4                                  0                                    0                                      0
  30     CCDC69          2                                  0                                    0                                      0
  31     IQGAP3          1                                  0                                    0                                      0
  32     PCDH9           3                                  1                                    0                                      0
  33     SYNPO2          7                                  0                                    3                                      0
  34     STIL          21                                   0                                    0                                      1
  35     GLDN            2                                  0                                    0                                      0
  36     CCDC85A         1                                  0                                    0                                      0
  37     GPM6B           4                                  0                                    0                                      0
  38     ITIH5           5                                  4                                    1                                      1
  39     AOX1            3                                  0                                    0                                      0
  40     NUSAP1          2                                  0                                    0                                      0
  41     ACSS3           1                                  0                                    0                                      0
  42     TCEAL2          1                                  0                                    0                                      0
  43     INMT            3                                  0                                    0                                      1

###### 

Meta-analysis of differentially expressed genes in the six microarray datasets.

  Gene symbol        Probe ID       I^2^ (%)   Q        df   P-value
  ------------------ -------------- ---------- -------- ---- ----------
  ANGPT1             205608_s\_at   96.10      129.21   5    \<0.0001
  AOX1               205083_at      86.20      36.33    5    \<0.0001
  BIRC5              202095_s\_at   97.00      167.98   5    \<0.0001
  CAV1               212097_at      91.80      60.9     5    \<0.0001
  CAV2               203323_at      90.10      50.61    5    \<0.0001
  CDKN1C             213348_at      92.60      67.89    5    \<0.0001
  CFD                205382_s\_at   95.90      120.82   5    \<0.0001
  CLU                208791_at      0.00       2.97     5    0.7051
  DPT                213068_at      76.10      20.93    5    0.0008
  DPT                207977_s\_at   0.00       4.25     5    0.5133
  EFEMP1             201843_s\_at   1.10       5.05     5    0.4094
  ERG                213541_s\_at   96.20      131.24   5    \<0.0001
  EZH2               203358_s\_at   97.00      164.74   5    \<0.0001
  FAM107A            209074_s\_at   99.00      507.18   5    \<0.0001
  FERMT2             209209_s\_at   89.10      46       5    \<0.0001
  FHL1               210299_s\_at   86.80      37.87    5    \<0.0001
  FXYD6              217897_at      27.10      6.86     5    0.2311
  GPM6A              209469_at      97.90      235.98   5    \<0.0001
  GPM6B              209168_at      86.10      35.99    5    \<0.0001
  HSPB8              221667_s\_at   65.50      14.47    5    0.0129
  ID4                209292_at      0.00       3.43     5    0.6338
  KCNAB1             210078_s\_at   64.50      14.1     5    0.015
  KIF4A              218355_at      95.80      119.67   5    \<0.0001
  LAPTM4B            208767_s\_at   96.90      163.18   5    \<0.0001
  MCAM /// MIR6756   210869_s\_at   0.00       4.61     5    0.4657
  MYH11              201496_x\_at   91.50      58.49    5    0.001
  MYL9               201058_s\_at   73.80      19.12    5    0.0018
  MYLK               202555_s\_at   90.00      49.86    5    \<0.0001
  NTRK2              221796_at      88.60      43.8     5    \<0.0001
  NUSAP1             218039_at      97         177.64   5    \<0.0001
  PCDH9              219737_s\_at   89.30      46.86    5    \<0.0001
  PPAP2B             212226_s\_at   0.00       4.65     5    0.4606
  PTRF               208789_at      82.20      28.16    5    \<0.0001
  STIL               205339_at      95.20      103.46   5    \<0.0001
  TCEAL2             211276_at      76.30      21.11    5    0.0008
  TIMP3              201147_s\_at   86.80      37.77    5    \<0.0001
